Bio Pharma Reporter caught up with several key players to find out what they are planning to showcase at the event and their key objectives.
Samsung Biologics
BPR: What will Samsung Biologics be showing at CPHI?
As a customised CDMO solutions provider, Samsung Biologics will showcase how it is technologically and operationally prepared to meet the varying needs of global pharma companies and biotechs of all sizes. We will demonstrate how our strengthened CMC (chemistry, manufacturing and controls) services with our new proprietary development platforms — S-KiH and S-Glyn — can bring tailored solutions to drug development projects of any characteristics. Furthermore, we will provide insights on our enhanced multimodality capabilities with the construction of an ADC facility, which will be cGMP ready in 2024, and our capacity expansion with the ground-breaking of Plant 5, the first plant in our second Bio Campus.
BPR: What does Samsung Biologics hope to achieve from the event?
Samsung Biologics hopes to provide visitors with the opportunity to see how we are continuously driving new possibilities to provide a seamless end-to-end CDMO service to our global partners. From maximising the potential of our clients’ molecules to the timely manufacture and delivery of drug products, our one-stop CDMO service is available for those who hope to maximise the effectiveness and quality of their products sustainably.
Purolite
BPR: What will Purolite be showcasing at CPHI Barcelona?
CPHI is one of the most established and well-attended pharma events globally. As our industry continues to evolve, we will need to continue to be at the forefront of that, so CPHI offers a great opportunity for networking on a grand scale with existing and potential new customers.
Purolite, an Ecolab company, will be showcasing its portfolio of products designed for pharma including solutions covering API’s and excipients, milling media and downstream bioprocessing purification on stand 6J39.
We will also be highlighting Ecolab’s commitment to life sciences and collaboration through our pharma enterprise solutions team. They will be showcasing their offering across the Ecolab portfolio of brands as a total solution for pharma.
BPR: What does Purolite hope to achieve from the event?
The pharma sector is very much a people-focused industry and collaboration is key, so we’re always looking for new ways to engage with delegates who attend the event. There’s nothing like meeting people face-to-face to discuss projects and help nurture deeper, more meaningful relationships. This way attendees get a real feel for who we are, the innovative solutions we provide and the culture of our business.
The main objective for participating in CPHI Barcelona includes engaging with current customers, meeting prospects interested in our solutions, and having technical experts available to assist with customer challenges. The event is a regular fixture on Purolite’s events calendar, presenting an excellent opportunity to introduce our offering to a broader audience. We’re excited to exhibit and look forward to CPHI 2023.
Sharp
BPR: What will Sharp be showing at CPHI?
Sharp will be showing its full range of commercial packaging solutions for biopharma drug products, including secondary packaging of injectables, blisters and bottles for solid oral dose formats, labelling and packaging of vials and syringes, pre-filled syringes and auto-injector assembly, labelling and packaging, and multi-component kitting. Our team will be available to advise and take questions on packaging-related topics, such as managing launches in multiple markets, rapid launches, serialisation and support for sustainable solutions. Finally, we will have an expert from our clinical services team available to discuss our services for clinical trial supply and optimisation from phase 1 trial through to commercialisation as well as technology solutions specifically for trial management.
BPR: What does Sharp hope to achieve from the event?
As well as meeting many of our existing clients, Sharp is looking forward to meeting new biopharma companies who are looking for specialists in commercial packaging and clinical trial services. CPHI remains the biggest opportunity in the industry to network with clients, prospects and peers together in one place. It is a uniquely productive environment that allows us to progress business relationships and identify innovations. Sustainability remains an imperative for Sharp and our whole industry and so we will also be having discussions with our suppliers to understand what new materials and services they are offering that we in turn can bring to the attention of our clients. Finally, our team is hoping for some all-important downtime together in the evenings, so we can relax and reflect on the privilege of working in the pharma industry.
Catalent
BPR: What will Catalent be showing at CPHI?
Catalent’s theme for this year’s CPHI is 'Your Pathway to Success'. As we know, the path to the next milestone can be very complicated for innovators both large and small, and at Catalent, we aim to help drug sponsors reach and surpass the next milestone as seamlessly as possible. To that effect, Catalent’s Biologics segment is excited to showcase our platform offerings across traditional biologics and advanced therapies. Our platform is designed to help innovators develop robust, scalable GMP manufacturing solutions to supply patients from clinical through commercial supply.
BPR: What does Catalent hope to achieve from the event?
Catalent is looking forward to meeting with drug sponsors from across the globe at its stand (3N50) to discuss their needs as they advance their therapies into the clinic and through commercialisation. Additionally, we are honoured to be finalists in the CPHI Pharma Awards in the API Development category, for our UpTempo AAV platform, and in the Supply Chain Excellence category for our Case Management Services. We look forward to the CPHI Awards dinner and an opportunity to celebrate with our fellow esteemed finalists and winners.
